Literature DB >> 12590242

Candesartan cilexetil-induced severe hepatotoxicity.

Giorgio Basile1, Daniela Villari, Sebastiano Gangemi, Tiziana Ferrara, Maria G Accetta, Vittorio Nicita-Mauro.   

Abstract

We report a case of severe hepatotoxicity associated with ductopenia in a 61-year-old woman. The patient developed jaundice, vomiting, and abdominal pain a few weeks after the beginning of treatment with candesartan cilexetil, 16 mg/d, for essential hypertension. Liver biopsy showed parenchymal bilirubinostasis with portal cholangitis and ductopenia. The drug was immediately withdrawn, and in the following weeks, aminotransferases and serum bilirubin returned to normal levels. The clinical-histologic data and the exclusion of known causes of liver disease led us to make a diagnosis of drug-induced cholestasis. To our knowledge, this is the first description of severe hepatotoxicity associated with ductopenia caused by an adverse reaction to candesartan cilexetil.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590242     DOI: 10.1097/00004836-200303000-00017

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

Review 1.  Noncholestatic acute hepatocellular injury following candesartan administration.

Authors:  Jan Antonio Lammel-Lindemann; Eduardo Flores-Villalba; Alexandro Jose Martagón; Eduardo DeObeso-Gonzalez; Francisco Puente-Gallegos
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

2.  Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers.

Authors:  Won Joon Choi; Gi-Ae Kim; Jaewon Park; Sangmi Jang; Woo Jin Jung; Jae-Jun Shim; Yewan Park; Gwang Hyeon Choi; Jin-Wook Kim; Sook-Hyang Jeong; Eun Sun Jang
Journal:  J Korean Med Sci       Date:  2022-08-22       Impact factor: 5.354

3.  Angiotensin II protects primary rat hepatocytes against bile salt-induced apoptosis.

Authors:  Golnar Karimian; Manon Buist-Homan; Bojana Mikus; Robert H Henning; Klaas Nico Faber; Han Moshage
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

4.  Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report.

Authors:  Dae Hwa Park; Gee Young Yun; Hyuk Soo Eun; Jong Seok Joo; Ju Seok Kim; Sun Hyung Kang; Hee Seok Moon; Eaum Seok Lee; Byung Seok Lee; Kyung Hee Kim; Seok Hyun Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.